Key facts
- It has raised $62.2M; the latest was Early Stage VC ($53.0M) in Jan 2026.
- Notable investors include Plug and Play Tech Center, Google for Startups, Endeavor Catalyst, DST Global, Norrsken VC — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Biorce
- ·The full record, as it builds
Funding rounds
No funding rounds for Biorce are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biorce
Developer of an artificial intelligence platform designed to accelerate clinical trial planning and execution. The company's platform offers AI-driven protocol design, feasibility assessment, regulatory planning, and explainable decision-making tools, enabling clinical teams and pharmaceutical organizations to reduce trial preparation time and manage study processes.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2024
- Employees
- 120
- Website
- biorce.com/
- Ownership
- Privately Held (backing)
Biorce doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biorce shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biorce in its N-PORT filings yet. We sweep new filings monthly.